Literature DB >> 16884384

Expression of matrix metalloproteinase-2 and mutant p53 is increased in hydatidiform mole as compared with normal placenta.

P Petignat1, R Laurini, F Goffin, I Bruchim, P Bischof.   

Abstract

Matrix metalloproteinases (MMPs) are group of enzymes thought to play an important role in trophoblastic and tumor invasion. The aim of our study was to investigate the trophoblastic expression of MMPs and p53 in normal trophoblast and hydatidiform moles (HM). Paraffin sections of 45 specimens, including 14 complete hydatidiform moles (CM), 15 partial hydatidiform moles (PM), 8 atypical partial hydatidiform moles (aPM), and 8 controls were selected. Classification of HM was established on histologic criteria and supported by the DNA ploidy results. Tissue sections from each case were immunostained with monoclonal antibodies, cytokeratin-7, MMP-2, MMP-9, tissue inhibitors of metalloproteinases (TIMP)-1, and p53 wild type (p53wt) and mutant types (mutp53). Staining for cytokeratin-7 revealed a positive reaction in 93% of the samples. MMP-2 was mainly expressed in the syncytiotrophoblast of HM and found in 62% of aPM, 60% PM, and 93% CM. The mutp53 was mainly and focally expressed in syncytiotrophoblastic cells and was found in 63% of aPM, 80% PM, and 93% CM. Expression of MMP-2 and mutp53 was both significantly greater in HM vs control group (P < 0.05) and greater in CM vs PM and aPM (P < 0.05). No significant difference was observed for cytokeratin-7, MMP-9, TIMP-1, and p53wt between the HM subgroups and between HM and control group. MMP-2 and mutp53 are overexpressed in HM as compared with normal trophoblast and might participate in the invasive behavior of the HM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884384     DOI: 10.1111/j.1525-1438.2006.00643.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Immunohistochemical Analysis of E-Cadherin, p53 and Inhibin-α Expression in Hydatidiform Mole and Hydropic Abortion.

Authors:  Onur Erol; Dinç Süren; Birsel Tutuş; Tayfun Toptaş; Ahmet Arda Gökay; Aysel Uysal Derbent; Mustafa Kemal Özel; Cem Sezer
Journal:  Pathol Oncol Res       Date:  2015-12-18       Impact factor: 3.201

2.  Mechanisms of matrix metalloproteinase-2 (mmp-2) transcriptional repression by progesterone in jar choriocarcinoma cells.

Authors:  Shlomit Goldman; David H Lovett; Eliezer Shalev
Journal:  Reprod Biol Endocrinol       Date:  2009-05-09       Impact factor: 5.211

3.  Protein phosphatase 1A (PPM1A) is involved in human cytotrophoblast cell invasion and migration.

Authors:  Baohua Zhang; Zhi Zhou; Haiyan Lin; Xiaoyin Lv; Jiejun Fu; Ping Lin; Cheng Zhu; Hongmei Wang
Journal:  Histochem Cell Biol       Date:  2009-04-29       Impact factor: 4.304

4.  Immunohistochemistry Study of P53 and C-erbB-2 Expression in Trophoblastic Tissue and Their Predictive Values in Diagnosing Malignant Progression of Simple Molar Pregnancy.

Authors:  Malihe Hasanzadeh; Norrie Sharifi; Marjaneh Farazestanian; Seyed Saman Nazemian; Faezeh Madani Sani
Journal:  Iran J Cancer Prev       Date:  2016-06-13

5.  P53 expression in various types of hydropic placentas (through ploidy analysis as a complementary tool in diagnosis of samples).

Authors:  Alireza Khooei; Fatemeh Atabaki Pasdar; Alireza Fazel; Mahmoud Mahmoudi; Mohammad Reza Nikravesh; Shahrzad Daneshmand Shahbazian
Journal:  Caspian J Intern Med       Date:  2019

6.  Ets-2 and p53 mediate cAMP-induced MMP-2 expression, activity and trophoblast invasion.

Authors:  Elsebeth Staun-Ram; Shlomit Goldman; Eliezer Shalev
Journal:  Reprod Biol Endocrinol       Date:  2009-11-25       Impact factor: 5.211

Review 7.  Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer.

Authors:  Bryan E Strauss; Gissele Rolemberg Oliveira Silva; Igor de Luna Vieira; Otto Luiz Dutra Cerqueira; Paulo Roberto Del Valle; Ruan Felipe Vieira Medrano; Samir Andrade Mendonça
Journal:  Clinics (Sao Paulo)       Date:  2018-09-06       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.